SCHEMBL10293180

SCHEMBL10293180

CC1CCN(S(=O)(=O)c2ccc3[nH]c(C(=O)NC4CCCC4)cc3c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.60
MEN1 O00255 2/20 0.57
MLLT1 Q03111 1/20 0.56
ALDH1A1 P00352 4/20 0.55
POLB P06746 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 2/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.49
LMNA P02545 1/20 0.49
MCOLN3 Q8TDD5 1/20 0.49
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8276818 0.99 KMT2A (0.62) KMT2AMEN1MLLT1ALDH1A1POLB
SCHEMBL10293176 0.91 ALDH1A1 (0.61) KMT2AMEN1MLLT1ALDH1A1POLB
SCHEMBL10293112 0.91 ALDH1A1 (0.61) KMT2AMEN1MLLT1ALDH1A1POLB
SCHEMBL10293126 0.89 CNR1 (0.57) KMT2AMLLT1ALDH1A1TDP1KDM4E
SCHEMBL8276779 0.88 CNR1 (0.58) KMT2AMLLT1ALDH1A1TDP1KDM4E
SCHEMBL1156383 0.88 KMT2A (0.56) KMT2AMEN1ALDH1A1POLBHSD17B10
SCHEMBL10293124 0.87 KMT2A (0.61) KMT2AMEN1ALDH1A1POLBHSD17B10
SCHEMBL10293113 0.87 KMT2A (0.58) KMT2AMEN1ALDH1A1POLBHSD17B10
SCHEMBL10293240 0.84 MEN1 (0.58) KMT2AMEN1ALDH1A1POLBHSD17B10
SCHEMBL10293150 0.84 CNR1 (0.52) KMT2AMEN1MLLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C KMT2A 3808/4885MEN1 3121/4885MLLT1 4258/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C KMT2A 3808/4885MEN1 3121/4885MLLT1 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.